News | January 18, 2013

Compact Proton Therapy Technology Achieves Milestone of Beam at Gantry Room Isocenter

ProTom Radiance 330

January 18, 2013 — Testing of a compact cancer treatment technology from ProTom International Inc. has demonstrated that the system achieves its design specification: delivering high-energy protons to isocenter at a beam intensity sufficient for standard clinical practice. The ProTom technical team measured stable and reproducible performance on the Radiance 330 proton therapy system at the McLaren Proton Therapy Center (MPTC) in Flint, Mich. This is the first time that ProTom has tested its compact system’s gantry beam optics design.

“Measuring high beam intensities at isocenter indicates well-functioning integration among various subsystems of the Radiance 330 necessary for clinical implementation,” said Vahagn Nazaryan, Ph.D., senior vice president of physics for ProTom. “We delivered beam through the gantry and nozzle in the first of three gantry treatment rooms as part of validation and verification of our technical design. We are pleased that the system performed as designed and quickly achieved a dose rate sufficient for standard clinical practice.”

“We are excited by the results of successful beam transport testing through our first gantry treatment room: these results were independently reproduced by our clinical physics team,” said Sung Park, Ph.D., chief physicist for McLaren Cancer Institute.

Earlier in the summer, ProTom installed a new custom-designed radiofrequency quadrupole (RFQ) proton linear accelerator (linac) injector from AccSys Technology Inc. This upgrade has significantly improved accelerated proton beam intensities. The RFQ upgrade resulted in an increase in injection intensity, yielding in excess of several times the number of protons per cycle accelerated in the synchrotron, with further tuning and optimization ongoing at McLaren.

“Both the ProTom and McLaren teams are to be commended for achieving this very significant result, which continues to validate that the system is performing as it was designed,” said ProTom CEO Stephen L. Spotts. “ProTom is focused on final validation and testing in order to secure all regulatory clearances necessary for clinical operation. It is my firm belief that our Radiance 330 system is not only the most advanced proton beam scanning system available but the most economical solution as well.“

The Radiance 330 proton therapy system has not been cleared by the U.S. Food and Drug Administration (FDA) for commercial distribution in the United States at this time.

For more information:,

Related Content

DOSIsoft Releases ISOgray Proton Therapy Treatment Planning System
Technology | Treatment Planning | August 15, 2017
DOSIsoft SA announced the official release, with CE marking, of ISOgray Treatment Planning System (TPS) release 4.3 for...
First Radixact Results Presented at AAPM 2017
News | Radiation Therapy | August 10, 2017
Accuray Inc. announced that the first studies validating the benefits of the Radixact System were presented at the 59th...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
Aktina’s interchangeable cones are lightweight and extremely accurate
News | Radiation Therapy | August 02, 2017
Aktina Medical announced a collaboration with Philips Medical Systems and Elekta Instruments for SRS interlocking at...
News | Image Guided Radiation Therapy (IGRT) | July 31, 2017
Elekta’s magnetic resonance radiation therapy (MR/RT) system will be the subject of 21 abstracts at the 59th American...
Accuray Receives 510(k) Clearance for iDMS Data Management System
Technology | Oncology Information Management Systems (OIMS) | July 31, 2017
July 31, 2017 — Accuray Inc. announced it has received 510(k) clearance from the U.S.
more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
Radiotherapy Prior to Surgery Reduces Secondary Tumor Risk in Early-Stage Breast Cancer Patients
News | Radiation Therapy | July 24, 2017
Moffitt Cancer Center researchers launched a first-of-its-kind study comparing the long-term benefits of radiation...
Overlay Init